Medical company Sensus Healthcare Inc (Nasdaq:SRTS ) revealed on Monday the completion of its public offering of 2,205,882 common stock, par value USD0.01 per share.
All of the common stock shares were offered by the company at a public offering price of USD6.80 per share.
Before deducting underwriting discounts and commissions and estimated offering expenses, the company raised total proceeds from the offering of about USD15m.
The company has provided the underwriters with a 30-day option to purchase up to another 330,882 shares at the public offering price, less underwriting discounts and commissions.
Net proceeds from the offering may be used by the company primarily for general corporate purposes, research and development activities, expansion of its product lines and roll-out of new product offerings, capital expenditures, selling, general and administrative costs, facilities expansion as well as working capital.
For the offering, B Riley FBR acted as the lead underwriter and sole book-running manager. Craig-Hallum Capital Group and Roth Capital Partners acted as co-managers.
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study
Precision Epigenomics partners with TruDiagnostic
Modalis partners with Ginkgo Bioworks
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Algiax Pharmaceuticals reveals update on chronic neuropathic pain study